Literature DB >> 2787379

Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

P L Ward1, H Koeppen, T Hurteau, H Schreiber.   

Abstract

We have isolated UV light-induced and spontaneous tumors along with nonmalignant cells and tissues from each host. CD8+ CTL clones generated to a number of highly immunogenic UV-induced tumors did not react with autologous normal fibroblasts nor with autologous second tumors. Using up to 25 independently induced tumors as targets, these CTL clones were found to be uniquely specific for the particular tumor used for immunization even when multiple tumors isolated from the same animals were used as targets. In addition to this extensive antigenic diversity of independently induced tumors, we found that a single cancer cell can express multiple independent antigens that were uniquely expressed on the tumor but were not detectable on autologous nonmalignant fibroblasts. A poorly immunogenic spontaneous tumor was also found to express an antigen that was uniquely specific for the immunizing tumor in that it was absent from any of 25 other tumors tested. This antigen was recognized by a mAb and not detected on autologous nonmalignant fibroblasts or on an autologous second spontaneous tumor. These findings demonstrate that syngeneic CTL clones or mAbs can define unique antigens on UV-induced or spontaneous tumors. The use of autologous nonmalignant fibroblast targets made it unlikely that these antigens were widely expressed on normal cells. The availability of cloned immunological probes to antigens on tumors isolated with autologous normal cells will allow a reliable identification of the genetic origins of unique antigens on experimentally induced and spontaneous tumors and permit a decisive answer to whether these unique antigens are encoded by normal genes or by genes that have undergone somatic mutations; i.e., whether these antigens are truly tumor specific.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787379      PMCID: PMC2189372          DOI: 10.1084/jem.170.1.217

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

2.  Nonvirus-associated antigens in virus-induced mouse mammary tumors.

Authors:  J Vaage
Journal:  Cancer Res       Date:  1968-12       Impact factor: 12.701

3.  The area-code hypothesis: the immune system provides clues to understanding the genetic and molecular basis of cell recognition during development.

Authors:  L Hood; H V Huang; W J Dreyer
Journal:  J Supramol Struct       Date:  1977

4.  Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.

Authors:  C Philipps; M McMillan; P M Flood; D B Murphy; J Forman; D Lancki; J E Womack; R S Goodenow; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

5.  Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.

Authors:  R D Wortzel; J L Urban; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

Review 6.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

7.  Stepwise immunologic selection of antigenic variants during tumor growth.

Authors:  J L Urban; M L Kripke; H Schreiber
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

8.  Alloreactive cloned T cell lines. I. Interactions between cloned amplifier and cytolytic T cell lines.

Authors:  A L Glasebrook; F W Fitch
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

9.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures.

Authors:  J C Cerottini; H D Engers; H R Macdonald; T Brunner
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  41 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

3.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

4.  Antibody recognition of a unique tumor-specific glycopeptide antigen.

Authors:  Cory L Brooks; Andrea Schietinger; Svetlana N Borisova; Peter Kufer; Mark Okon; Tomoko Hirama; C Roger Mackenzie; Lai-Xi Wang; Hans Schreiber; Stephen V Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

5.  Densely granulated murine NK cells eradicate large solid tumors.

Authors:  Rebecca B Liu; Boris Engels; Ainhoa Arina; Karin Schreiber; Elizabeth Hyjek; Andrea Schietinger; David C Binder; Eric Butz; Thomas Krausz; Donald A Rowley; Bana Jabri; Hans Schreiber
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

6.  Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.

Authors:  S Balachandran; M Porosnicu; G N Barber
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

8.  Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.

Authors:  T Kitajima; M Iwashiro; K Kuribayashi; S Imamura
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

9.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

Authors:  Haidong Tang; Yang Wang; Lukasz K Chlewicki; Yuan Zhang; Jingya Guo; Wei Liang; Jieyi Wang; Xiaoxiao Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

10.  Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Authors:  Shilin Yang; Yi Yang; John Raycraft; Hongtao Zhang; Sandra Kanan; Yajun Guo; Ze'ev Ronai; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.